GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (FRA:IQI) » Definitions » EPS (Diluted)

Incannex Healthcare (FRA:IQI) EPS (Diluted) : €-0.01 (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Incannex Healthcare EPS (Diluted)?

Incannex Healthcare's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.01.

Incannex Healthcare's EPS (Basic) for the three months ended in Mar. 2024 was €0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.01.

Incannex Healthcare's EPS without NRI for the three months ended in Mar. 2024 was €0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.01.

During the past 3 years, the average EPS without NRIGrowth Rate was -499.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -250.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was -63.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Incannex Healthcare's highest 3-Year average EPS without NRI Growth Rate was 72.00% per year. The lowest was -499.20% per year. And the median was -35.55% per year.


Incannex Healthcare EPS (Diluted) Historical Data

The historical data trend for Incannex Healthcare's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare EPS (Diluted) Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.96 -1.18

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 - - -

Competitive Comparison of Incannex Healthcare's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incannex Healthcare's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's PE Ratio distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's PE Ratio falls into.



Incannex Healthcare EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Incannex Healthcare's Diluted EPS for the fiscal year that ended in Jun. 2022 is calculated as

Diluted EPS (A: Jun. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-9.699-0)/1191.154
=-0.01

Incannex Healthcare's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.549-0)/1587.01
=-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incannex Healthcare  (FRA:IQI) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Incannex Healthcare EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (FRA:IQI) Business Description

Traded in Other Exchanges
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.